Zostavax Immunisation Leads to Death
09 Mar 2017
It has been reported that an elderly man died in NSW due to fatal, widespread zoster virus infection following vaccination with Zostavax. He should not have been vaccinated due to significant underlying health conditions.
The Zostavax program for 70-79 year old patients was launched in November 2016. The vaccine is contra-indicated in patients who are immunocompromised. Zostavax is a live attenuated vaccine, and administration to patients who are immunocompromised can lead to disseminated disease and death.
If there is doubt about whether Zostavax is safe for a patient, defer vaccination and seek specialist advice. If Zostavax is given to an immunocompromised patient, urgently contact the treating specialist or infectious disease specialist for advice on use of antivirals.
Further information is available:
- National Centre for Immunisation Research & Surveillance Fact Sheet
- On-line version of the Australian Immunisation handbook.
This blog contains general information only. We recommend you contact your medical defence organisation or insurer when you require specific advice in relation to medico-legal matters. This blog is based on an actual event but details have been changed to protect the privacy of those involved.
A health practitioners guide to social media
What are the laws and guidelines that impact social media for practitioners?
22 Jul 2025
Patient Autonomy in Australian Medical care
Do we really support patient autonomy in the decision-making process?
22 Jul 2025
Practicalities of Medicare
Do you understand the Medicare system and are you confident that your billing processes comply with requirements?
22 Jul 2025
Understanding changes to the Fair Work Act
What are the changes to the Fair Work Act and what is my role?
22 Jul 2025